Additional Proxy Soliciting Materials (definitive) (defa14a)
February 05 2013 - 5:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): February 1, 2013
SOMAXON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
000-51665
|
|
20-0161599
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
440 Stevens Avenue, Suite 200, Solana Beach, CA
|
|
92075
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858) 876-6500
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
x
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01
|
Entry Into a Material Definitive Agreement
|
On February 1, 2013, Somaxon Pharmaceuticals, Inc. (Somaxon) and its licensor ProCom One, Inc. entered into a Settlement and License Agreement (the Agreement) with Actavis
Elizabeth LLC and Actavis Inc. (collectively, Actavis) to resolve the pending patent litigation between the parties involving Actavis application seeking approval to market a generic version of Silenor
®
(doxepin) 3 mg and 6 mg tablets.
Under the Agreement, Somaxon agreed to grant Actavis a non-exclusive, royalty-bearing license under the patents that are the subject of
the litigation, U.S. Patent Nos. 6,211,229 and 7,915,307 (the Litigated Patents), to sell a generic version of Silenor in the United States beginning January 1 , 2020, or earlier under certain circumstances. Such circumstances include
the sale in the United States of a generic equivalent version of Silenor by a third party and a final court decision that the Litigated Patents are not infringed, invalid or unenforceable.
The Agreement provides that Somaxon and Actavis will not pursue litigation activities related to the pending litigation and will file a
dismissal order with respect to the pending litigation within three business days following the execution of the Agreement. Under the Agreement, Somaxon will make payments to Actavis in recognition of the savings inuring to Somaxon in terms of the
avoidance of costs and burden associated with prosecuting the litigation. The Agreement provides that Somaxon and Actavis will submit the Agreements to the U.S. Federal Trade Commission and the U.S. Department of Justice within ten business days
following the date of execution.
The Agreement also contains provisions regarding indemnification, confidentiality, dispute
resolution and other customary provisions for agreements of these kinds.
The foregoing summary of the Agreement is qualified
in its entirety by reference to the full text of the Agreement, a copy of which will be filed as an exhibit to Somaxons Quarterly Report on Form 10-Q for the quarter ending March 31, 2013.
Item 7.01.
|
Regulation FD Disclosure
|
On February 5, 2013, Somaxon issued a press release announcing, among other things, the signing of the Agreement with Actavis. The full
text of such press release is furnished as Exhibit 99.1 to this report.
The foregoing information in Item 7.01 of this
Current Report on Form 8-K, together with the press release attached hereto as Exhibit 99.1, is being furnished pursuant to this Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made
before or after the date hereof, except as expressly set forth by specific reference in such filing to Item 7.01 of this Current Report on Form 8-K.
By filing this Current Report on Form 8-K and furnishing this information, Somaxon makes no admission as to the materiality of Item 7.01 in this report or the press release attached hereto as Exhibit
99.1. The information contained in the press release is summary information that is intended to be considered in the context of Somaxons filings with the Securities and Exchange Commission and other public announcements that Somaxon makes, by
press release or otherwise, from time to time.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits.
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press Release, dated February 5, 2013
|
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SOMAXON PHARMACEUTICALS, INC.
|
Date: February 5, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Matthew W. Onaitis
|
|
|
|
|
Name:
|
|
Matthew W. Onaitis
|
|
|
|
|
Title:
|
|
Senior Vice President and General Counsel
|
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press Release, dated February 5, 2013
|
Somaxon (NASDAQ:SOMX)
Historical Stock Chart
From May 2024 to Jun 2024
Somaxon (NASDAQ:SOMX)
Historical Stock Chart
From Jun 2023 to Jun 2024